TY - JOUR
T1 - Drug evaluation
T2 - AMG-531 for the treatment of thrombocytopenias
AU - Rice, Lawrence
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2006/9
Y1 - 2006/9
N2 - Amgen Inc is developing AMG-531, a peptibody that binds to the thrombopoietin receptor Mpl, for the potential treatment of immune thrombocytopenic purpura (ITP), chemotherapy-induced thrombocytopenia (CIT) and thrombocytopenia in myelodysplastic syndrome (MDS). Results of the US phase III trial in ITP are expected to be available in the second half of 2006, while a phase II trial in CIT is still underway. A Japanese phase II ITP study has been initiated, as has a phase II trial of MDS patients in the US and France.
AB - Amgen Inc is developing AMG-531, a peptibody that binds to the thrombopoietin receptor Mpl, for the potential treatment of immune thrombocytopenic purpura (ITP), chemotherapy-induced thrombocytopenia (CIT) and thrombocytopenia in myelodysplastic syndrome (MDS). Results of the US phase III trial in ITP are expected to be available in the second half of 2006, while a phase II trial in CIT is still underway. A Japanese phase II ITP study has been initiated, as has a phase II trial of MDS patients in the US and France.
UR - http://www.scopus.com/inward/record.url?scp=33748674848&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748674848&partnerID=8YFLogxK
M3 - Review article
C2 - 17002262
AN - SCOPUS:33748674848
SN - 1472-4472
VL - 7
SP - 834
EP - 841
JO - Current Opinion in Investigational Drugs
JF - Current Opinion in Investigational Drugs
IS - 9
ER -